Multiple myeloma is not a leukemia. Both are blood cancers, and both start in the bone marrow, which is why people often confuse them. But they arise from different cell types, behave differently in the body, produce different symptoms, and require different treatments.
Why They’re Different Cancers
The confusion makes sense: myeloma and leukemia are both classified as hematologic (blood) malignancies, and both involve white blood cells gone wrong. But the specific white blood cell involved is what separates them.
Multiple myeloma starts in plasma cells. These are mature immune cells whose normal job is to produce antibodies that fight infections. In myeloma, these plasma cells multiply uncontrollably inside the bone marrow and begin churning out a single, useless antibody protein called M-protein instead of the diverse antibodies your immune system needs.
Leukemia, by contrast, starts in immature blood cells called blasts. Acute myeloid leukemia (AML), the most common acute form in adults, originates in early myeloid cells that never fully develop. Other types like acute lymphoblastic leukemia (ALL) arise from immature lymphoid cells. The key distinction: leukemia involves cells that haven’t finished developing, while myeloma involves cells that have already matured into plasma cells and then turned cancerous.
Where Each Cancer Lives in the Body
Both cancers occupy the bone marrow, but they differ in what happens next. In leukemia, the abnormal cells typically flood into the bloodstream quickly. That’s partly why acute leukemia can cause symptoms that appear suddenly and escalate fast: the blood fills with nonfunctional cells that crowd out healthy red blood cells, white blood cells, and platelets.
Myeloma cells generally stay put in the bone marrow. They accumulate there, damaging the surrounding bone tissue rather than spilling into the bloodstream in large numbers. This is why myeloma’s hallmark problems center on bone destruction rather than the overwhelming blood abnormalities seen in acute leukemia.
How Symptoms Differ
Multiple myeloma has a distinctive pattern of damage that doctors refer to with the acronym CRAB: high calcium levels, renal (kidney) problems, anemia, and bone lesions. About 85% of people with myeloma develop some degree of bone damage or bone loss. The most commonly affected areas are the spine, pelvis, and rib cage. Weakened bones can fracture easily or collapse, particularly in the vertebrae, sometimes compressing the spinal cord.
The bone destruction happens because myeloma cells activate other cells in the marrow that break down bone tissue. This releases calcium into the blood, which can cause confusion, excessive thirst, nausea, and kidney damage. Meanwhile, the M-protein itself can clog the kidneys and impair their filtering ability.
Leukemia symptoms tend to reflect the crowding out of normal blood cells: fatigue and pallor from too few red blood cells, frequent infections from a shortage of functional white blood cells, and easy bleeding or bruising from low platelet counts. While myeloma also causes anemia, the bone pain, fractures, and kidney problems are much more specific to myeloma and rare in most leukemias.
Different Diagnostic Tests
The tests used to identify each cancer reflect their biological differences. Myeloma diagnosis relies heavily on detecting that abnormal M-protein. A blood test called serum protein electrophoresis looks for a characteristic “spike” in the protein pattern. A bone marrow biopsy then checks whether at least 10% of the marrow cells are cancerous plasma cells, and imaging scans look for the telltale holes in the bones (osteolytic lesions).
Leukemia diagnosis focuses on blood counts and bone marrow examination using a technique called flow cytometry, which identifies the specific type and maturity of the abnormal cells circulating in the blood and marrow. The distinction matters because the M-protein spike that defines myeloma is not a feature of most leukemias.
Interestingly, many myeloma cases are preceded by a precancerous condition called monoclonal gammopathy of undetermined significance, or MGUS. This is when the M-protein spike appears in a blood test but no organ damage has occurred yet and fewer than 10% of marrow cells are abnormal plasma cells. MGUS doesn’t always progress to myeloma, but it can, which is why it’s monitored over time.
The One Place They Overlap
There is a rare condition that blurs the line between these two cancers: plasma cell leukemia. This aggressive disease occurs when the abnormal plasma cells that normally stay in the bone marrow (as in typical myeloma) break into the bloodstream in large numbers, making up more than 5% of circulating white blood cells. It can develop on its own or as a transformation of existing myeloma.
Plasma cell leukemia accounts for only about 2% to 3% of all plasma cell cancers. It’s technically classified as the rarest and most aggressive form of multiple myeloma rather than a true leukemia, even though it behaves like one by flooding the blood. Its existence highlights why people sometimes conflate the two diseases, but it’s the exception rather than the rule.
Treatment Takes Different Paths
The treatment strategies for myeloma and leukemia have diverged significantly, reflecting their distinct biology. Myeloma treatment centers on drug classes developed specifically for plasma cell cancers. The backbone of modern myeloma therapy includes proteasome inhibitors, which block a system that plasma cells depend on to recycle proteins. Immunomodulatory drugs are another cornerstone, often combined with corticosteroids. Many patients also undergo stem cell transplant after initial treatment.
Leukemia treatment varies by type but often involves intensive chemotherapy designed to kill rapidly dividing immature cells. Certain leukemias, like chronic myeloid leukemia, are treated with targeted drugs that block a specific genetic mutation driving the cancer. The drug classes that work well for myeloma generally don’t overlap with those used in leukemia, and vice versa, precisely because the underlying cancer cells are so different.
Who Gets Each Disease
The demographics also differ. Multiple myeloma is typically diagnosed later in life, with a median age at diagnosis of 69. An estimated 36,110 new cases will be diagnosed in the United States in 2025, with roughly 12,030 deaths. Leukemia as a group is more variable: some types (like ALL) peak in children, while others (like chronic lymphocytic leukemia) primarily affect older adults. Overall, leukemia is more common than myeloma when all subtypes are counted together.
Both diseases have seen meaningful improvements in survival over the past two decades, driven by newer targeted therapies. But they remain distinct diagnoses with their own prognosis, treatment plans, and long-term management strategies. If you or someone you know has been diagnosed with either one, understanding that they are separate diseases is the first step toward navigating the right treatment path.